In 102 non-cirrhotic adults with presumed MASH (F1–F3), 12 weeks of the THR-β agonist ALG-055009 cut MRI-PDFF liver fat vs placebo; placebo-adjusted relative change −33.2% at 0.7 mg and −31.6% at 0.9 mg, not significant at 0.3 mg. No safety signals seen.
RCTn = 102
Loomba et al. ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial